Bio-Thera and STADA's Golimumab Biosimilar, 'Gotenfia,' Receives Final EMA Marketing Authorization
Final EU Marketing Authorization and Commercial Launch Achieved
Bio-Thera Solutions, a Chinese company, and STADA, a German company, have jointly achieved a significant milestone with their golimumab biosimilar, 'Gotenfia.' The biosimilar has received final marketing authorization from the European Commission (EC). This approval follows the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) in December 2025, with the official approval granted in February 2026. This regulatory approval allows Gotenfia to be prescribed in the 27 EU member states and the European Economic Area (EEA). STADA's acquisition of this approval significantly strengthens its immunology portfolio and positions it for greater dominance in the European biosimilar market.
Demonstrated Equivalence and Safety Through Phase 3 Clinical Trials
The regulatory approval of Gotenfia is based on data from Phase 3 clinical trials that demonstrated high therapeutic equivalence to the originator product, 'Simponi' from Janssen. The Phase 3 study involved patients with psoriatic arthritis and demonstrated equivalence in efficacy based on the ACR 20 (American College of Rheumatology 20% improvement criteria) at week 14. Furthermore, the studies confirmed no significant differences in pharmacokinetics, pharmacodynamics, and immunogenicity. By meeting the stringent biological equivalence criteria required by regulatory authorities, Gotenfia provides a reliable treatment option for healthcare professionals and patients.
License Agreement Terms and Financial Value Analysis
STADA and Bio-Thera entered into an exclusive license agreement in May 2024 for the commercialization of Gotenfia in Europe, the UK, and Switzerland. Under the agreement, Bio-Thera received an upfront payment of USD $10 million and is eligible for milestone payments of up to USD $147.5 million upon achieving certain milestones. Bio-Thera is responsible for manufacturing and global supply, while STADA manages the commercial operations in Europe, thereby sharing the risks. This marketing authorization serves as a direct trigger for the achievement of milestone payments, which will contribute to improving Bio-Thera's financial stability.
Penetration into the USD 3 Billion Golimumab Market and Competitive Outlook
The global golimumab market is estimated at approximately USD $3.1 to $3.5 billion annually, with the European market accounting for about 30% of the total. Given that golimumab is widely prescribed for chronic autoimmune diseases such as rheumatoid arthritis, the launch of Gotenfia is expected to significantly impact the European market. The introduction of biosimilars typically leads to a 30-50% price reduction compared to the originator product, which provides significant social benefits by reducing the financial burden on healthcare systems in Europe. STADA plans to leverage its strong marketing network to rapidly gain market share from the originator product.
The European marketing authorization for Gotenfia represents a short-term positive development as it triggers the realization of additional milestone payments under the USD $157.5 million license agreement signed in 2024. In the medium to long term, it signifies the beginning of a full-fledged competition for market share in the global USD $3.2 billion golimumab market, with Gotenfia directly competing against the originator product, Simponi, from Janssen. With STADA utilizing its European distribution network and leveraging price competitiveness, the market is expected to undergo rapid restructuring with a price reduction pressure of 30% or more compared to the originator product. Furthermore, with the availability of robust Phase 3 clinical data demonstrating complete therapeutic equivalence in patients with active psoriatic arthritis, Gotenfia provides a reliable alternative treatment option, which will be welcomed by healthcare professionals seeking to diversify their treatment options and by industry stakeholders eager to accelerate the adoption of biosimilars.
Source: EMA (ema)